Skip to main content

Advertisement

SpringerLink
Log in

Single brain metastasis

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

The management of single brain metastases has evolved substantially over the last decade. The advent of triple-dose contrast-enhanced MRI scans has improved the radiologists’ capacity to resolve small tumors, and, thereby, has resulted in a declining percentage of brain metastases classified as single. Only 25% to 30% of brain metastases are single; single brain metastases in the absence of systemic metastases are termed solitary. Randomized trials suggest that patients not in imminent danger of herniation are best managed initially with dexamethasone 2 to 4 mg administered orally twice daily. The routine use of prophylactic anticonvulsants is discouraged. Patients with refractory progressive systemic tumor likely to prove fatal within 3 to 6 months should receive fractionated whole brain radiotherapy. Patients with highly radiosensitive primary tumors such as small cell lung cancer, lymphoma, and germinoma should also receive whole brain radiotherapy. Patients with inactive or controllable systemic cancer and good performance status benefit from the addition of local strategies like surgery or radiosurgery to whole brain radiotherapy. Although surgery and radiosurgery have not been compared in a randomized controlled trial, data suggest that results are similar. Consequently, for most metastases that fall within the size constraints of radiosurgery (3.5 cm or smaller in diameter), radiosurgery is preferred for its relatively noninvasive nature. Patients with larger or cystic tumors, with obstructive hydrocephalus, or neurologic instability despite corticosteroids are best treated with craniotomy. Fractionated whole brain radiation following surgical or radiosurgical management of single brain metastasis appears to decrease the risk of recurrent brain metastasis, although it has not been shown to improve survival. We recommend its use in most patients, although patients with tumors likely to be highly resistant to fractionated radiotherapy or at high risk of radiation neurotoxicity may reasonably defer its use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schellinger PD, Meinck HM, Thron A: Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 1999, 44:275–281.

    Article  PubMed  CAS  Google Scholar 

  2. Yuh WT, Fisher DJ, Runge VM, et al.: Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases. AJNR Am J Neuroradiol 1994, 15:1037–1051.

    PubMed  CAS  Google Scholar 

  3. Yuh WT, Tali ET, Nguyen HD, et al.: The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. AJNR Am J Neuroradiol 1995, 16:373–380.

    PubMed  CAS  Google Scholar 

  4. Sze G, Johnson C, Kawamura Y, et al.: Comparison of single- and triple-dose contrast material in the MR screening of brain metastases. AJNR Am J Neuroradiol 1998, 19:821–828.

    PubMed  CAS  Google Scholar 

  5. Mayr NA, Yuh WT, Muhonen MG, et al.: Cost-effectiveness of high-dose MR contrast studies in the evaluation of brain metastases. AJNR Am J Neuroradiol 1994, 15:1053–1061.

    PubMed  CAS  Google Scholar 

  6. Thng CH, Tay KH, Chan LL, et al.: Magnetic resonance imaging of brain metastases: magnetisation transfer or triple dose gadolinium? Ann Acad Med Singapore 1999, 28:529–533.

    PubMed  CAS  Google Scholar 

  7. Peretti-Viton P, Taieb D, Viton JM, et al.: Contrastenhanced magnetisation transfer MRI in metastatic lesions of the brain. Neuroradiol 1998, 40:783–787.

    Article  CAS  Google Scholar 

  8. Diener-West M, Dobbins TW, Phillips TL, Nelson DF: Identification of an optimal subgroup for treatment evaluation of patients with brain metastases using RTOG study 7916. Int J Radiat Oncol Biol Phys 1989, 16:669–673.

    PubMed  CAS  Google Scholar 

  9. Lagerwaard FJ, Levendag PC, Nowak PJ, et al.: Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999, 43:795–803.

    Article  PubMed  CAS  Google Scholar 

  10. Agboola O, Benoit B, Cross P, et al.: Prognostic factors derived from recursive partition analysis (RPA) of Radiation Therapy Oncology Group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases. Int J Radiat Oncol Biol Phys 1998, 42:155–159.

    Article  PubMed  CAS  Google Scholar 

  11. Gaspar L, Scott C, Rotman M, et al.: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37:745–751. This analysis aids clinicians in deciding which patients have an adequate prognosis to warrant intensive local strategies for brain metastasis control.

    Article  PubMed  CAS  Google Scholar 

  12. Nieder C, Nestle U, Motaref B, et al.: Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes? Int J Radiat Oncol Biol Phys 2000, 46:297–302.

    Article  PubMed  CAS  Google Scholar 

  13. Vecht CJ, Hovestadt A, Verbiest HB, Van VJ, Van PW: Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994, 44:675–80.

    PubMed  CAS  Google Scholar 

  14. Sheline GE, Brady LW: Radiation therapy for brain metastases. J Neurooncol 1987, 4:219–225.

    Article  PubMed  CAS  Google Scholar 

  15. Epstein BE, Scott CB, Sause WT, et al.: Improved survival duration in patients with unresected solitary brain metastasis using accelerated hyperfractionated radiation therapy at total doses of 54.4 gray and greater. Results of Radiation Therapy Oncology Group 85–28. Cancer 1993, 71:1362–1367.

    Article  PubMed  CAS  Google Scholar 

  16. DeAngelis LM, Delattre JY, Posner JB: Radiationinduced dementia in patients cured of brain metastases. Neurology 1989, 39:789–796.

    PubMed  CAS  Google Scholar 

  17. Sneed PK, Larson DA, Wara WM: Radiotherapy for cerebral metastases. Neurosurg Clin N Am 1996, 7:505–515.

    PubMed  CAS  Google Scholar 

  18. PatchellRA, Tibbs PA, Regine WF, et al.: Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998, 280:1485–1489. This carefully conducted clinical trial demonstrates the benefits and limitations of postoperative radiotherapy following resection of a single brain metastasis.

    Article  PubMed  CAS  Google Scholar 

  19. Pirzkall A, Debus J, Lohr F, et al.: Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 1998, 16:3563–3569. Adjuvant fractionated radiotherapy improves local control but does not appear to improve survival, analagous to its role follwing operation.

    PubMed  CAS  Google Scholar 

  20. Sneed PK, Lamborn KR, Forstner JM, et al.: Radiosurgery for brain metastases: is whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys 1999, 43:549–558.

    Article  PubMed  CAS  Google Scholar 

  21. Patchell RA, Tibbs PA, Walsh JW, et al.: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322:494–500.

    Article  PubMed  CAS  Google Scholar 

  22. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al.: The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994, 29:711–717.

    PubMed  CAS  Google Scholar 

  23. Mintz AH, Kestle J, Rathbone MP, et al.: A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996, 78:1470–1476.

    Article  PubMed  CAS  Google Scholar 

  24. Shiau CY, Sneed PK, Shu HK, et al.: Radiosurgery for brain metastases: relationship of dose and pattern of enhancement to local control. Int J Radiat Oncol Biol Physi 1997, 37:375–383.

    Article  CAS  Google Scholar 

  25. Loeffler JS, Barker FG, Chapman PH: Role of radiosurgery in the management of central nervous system metastases. Cancer Chemother Pharmacol 1999, 43(suppl):S11-S14.

    Article  PubMed  Google Scholar 

  26. Peterson AM, Meltzer CC, Evanson EJ, et al.: MR imaging response of brain metastases after gamma knife stereotactic radiosurgery. Radiology 1999, 211:807–814.

    PubMed  CAS  Google Scholar 

  27. Alexander E, Moriarty TM, Davis RB, et al.: Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 1995, 87:34–40.

    Article  PubMed  Google Scholar 

  28. Kondziolka D, Patel A, Lunsford LD, et al.: Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 1999, 45:427–434. Adjuvant radiosurgery improves local control in patients with two to four brain metastases.

    Article  PubMed  CAS  Google Scholar 

  29. Lavine SD, Petrovich Z, Cohen-Gadol AA, et al.: Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications. Neurosurgery 1999, 44:59–64.

    Article  PubMed  CAS  Google Scholar 

  30. Huang CF, Kondziolka D, Flickinger JC, Lunsford LD: Stereotactic radiosurgery for brainstem metastases. J Neurosurgery 1999, 91:563–568.

    CAS  Google Scholar 

  31. Bindal AK, Bindal RK, Hess KR, et al.: Surgery versus radiosurgery in the treatment of brain metastasis. J Neurosurgery 1996, 84:748–754.

    Article  CAS  Google Scholar 

  32. Mehta M, Noyes W, Craig B, et al.: A cost-effectiveness and cost-utility analysis of radiosurgery vs. resection for single-brain metastases. Int J Radiat Oncol Biol Phys 1997, 39:445–454.

    Article  PubMed  CAS  Google Scholar 

  33. Bogart JA, Ungureanu C, Shihadeh E, et al.: Resection and permanent I-125 brachytherapy without whole brain irradiation for solitary brain metastasis from non-small cell lung carcinoma. J Neurooncol 1999, 44:53–57.

    Article  PubMed  CAS  Google Scholar 

  34. McDermott MW, Cosgrove GR, Larson DA, et al.: Interstitial brachytherapy for intracranial metastases. Neurosurg Clin N Am 1996, 7:485–495.

    PubMed  CAS  Google Scholar 

  35. Cohen N, Strauss G, Lew R, et al.: Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis. J Clin Oncol 1988, 6:1621–1624.

    PubMed  CAS  Google Scholar 

  36. Glantz MJ, Cole BF, Friedberg MH, et al.: A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 1996, 46(4):985–991. This prospective trial showed no benefit in prevention of late seizures with prophylactic Depakote.

    PubMed  CAS  Google Scholar 

  37. Fetell MR, Grossman SA, Fisher JD, et al.: Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol 1997, 15:3121–3128. This was one of the first studies to highlight the prominent effects of several anticonvulsants on chemotherapy metabolism.

    PubMed  CAS  Google Scholar 

  38. GlantzMJ, Cole BF, Forsyth PA, et al.: Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology 2000, 54:1886–1893. Meta-analysis confirms the lack of benefit of prophylactic anticonvulsants.

    PubMed  CAS  Google Scholar 

  39. Schiff D, DeAngelis LM: Therapy of venous thromboembolism in patients with brain metastases. Cancer 1994, 73:493–498.

    Article  PubMed  CAS  Google Scholar 

  40. Decousus H, Leizorovicz A, Parent F, et al.: A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998, 338:409–415.

    Article  PubMed  CAS  Google Scholar 

  41. Levin JM, Schiff D, Loeffler JS, et al.: Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 1993, 43:1111–1114.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Neurologic Surgery, Neurology, and Medicine, University of Pittsburgh, Kaufman Building, Suite 802, 3471 Fifth Avenue, 15213, Pittsburgh, PA, USA

    David Schiff MD

Authors
  1. David Schiff MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schiff, D. Single brain metastasis. Curr Treat Options Neurol 3, 89–99 (2001). https://doi.org/10.1007/s11940-001-0027-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-001-0027-4

Keywords

Search

Navigation